Meridian Biotech in partnership with the University of Alabama-Birmingham (UAB) was awarded a National Institutes of Health (NIH) Phase 1 & 2 grant for biomedical research. Additional partners include: Boston Children’s Hospital (Harvard University); University of Oregon; and the University of Colorado Anschutz Medical Campus.
Findings from the NIH Phase I research conclusively showed that MRD-Pro, a high protein mixed microbial product, has statin-like properties to lower cholesterol, reduce body fat, and benefits the microbiome. This breakthrough is significant since the medical community, as well as today’s health-conscious consumers, recognize that the imbalance of normal gut microbiome has been linked with gastrointestinal conditions such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), and wider systemic manifestations of disease such as obesity, type 2 diabetes, and other diseases.
The research from NIH will allow Meridian Biotech to accelerate MRD-PRO into the human consumption market with government funding along with further research & development for the next two to three years.
Publications/Sources:
Zebrafish Danio rerio Exhibit Positive Growth Profiles when Fed Dietary Yeast and Bacterial-Based Single-Cell Protein as a Replacement for Fish Protein Hydrolysate
Williams et al., 2023: https://doi.org/10.1002/naaq.10299
Comments